以替吉奥为基础的化疗对改善消化道肿瘤安全性研究
|
摘要
目的研究以替吉奥作为基础的化疗方法在改善消化道肿瘤中的安全性。方法随机抽取68例于2016年7月至2017年9月收治的消化道肿瘤病人进行研究,分参照组与治疗组各34例,参照组采取氟尿嘧啶作为基础的常规治疗,治疗组采取的药物联合治疗则以替吉奥作为基础,对比两组安全性。结果治疗组疾病控制率是85.29%,参照组是64.71%;治疗组不良反应率是17.65%,参照组是41.18%;治疗组临床症状与生活质量的改善评分均比参照组高,两组各项指标对比P<0.05有统计学意义。结论以替吉奥作为基础化疗方法应用在消化道肿瘤中对改善病人症状安全性显著,值得推荐。
Objective to study the safety of tegafur,gimeracil and oteracil potassium as a basic chemotherapy in improving gastrointestinal tumors.Methods a total of 68 patients with gastrointestinal tumors admitted from July 2016 to September 2017 were randomly selected for study.Thirty-four cases were divided into the reference group and the treatment group,with the reference group taking fluorouracil as the basic routine treatment.In the treatment group,drug combination therapy was based on tegafur,gimeracil and oteracil potassium,and the safety of the two groups was compared.Results the control rate of disease was 85.29% in the treatment group and 64.71% in the reference group.The adverse reaction rate was 17.65% in the treatment group and 41.18% in the reference group.The improvement scores of clinical symptoms and quality of life in the treatment group were higher than those in the reference group,and the comparison of various indexes between the two groups showed statistically significant P < 0.05.Conclusiontegafur,gimeracil and oteracil potassium as a basic chemotherapy in gastrointestinal tumors can significantly improve the patient's symptom safety and is worthy of recommendation.
Objective to study the safety of tegafur,gimeracil and oteracil potassium as a basic chemotherapy in improving gastrointestinal tumors.Methods a total of 68 patients with gastrointestinal tumors admitted from July 2016 to September 2017 were randomly selected for study.Thirty-four cases were divided into the reference group and the treatment group,with the reference group taking fluorouracil as the basic routine treatment.In the treatment group,drug combination therapy was based on tegafur,gimeracil and oteracil potassium,and the safety of the two groups was compared.Results the control rate of disease was 85.29% in the treatment group and 64.71% in the reference group.The adverse reaction rate was 17.65% in the treatment group and 41.18% in the reference group.The improvement scores of clinical symptoms and quality of life in the treatment group were higher than those in the reference group,and the comparison of various indexes between the two groups showed statistically significant P < 0.05.Conclusiontegafur,gimeracil and oteracil potassium as a basic chemotherapy in gastrointestinal tumors can significantly improve the patient's symptom safety and is worthy of recommendation.
引文
[1]代晓楠,翁文采.替吉奥为基础的化疗在消化道肿瘤中安全性的观察与分析[J].航空航天医学杂志,2015,26(12):1475-1477.
[2]黎喜梅.替吉奥为基础的化疗在消化道肿瘤中疗效与安全性的观察分析[J].中外医学研究,2017,15(20):138-140.
[3]刘昌娟.替吉奥为基础的化疗在消化道肿瘤中疗效与安全性的观察分析[J].中国继续医学教育,2017,9(28):96-98.
[4]王永杰.消化道肿瘤患者口服替吉奥化疗的临床效果观察[J].中国医药指南,2018,16(08):154-155.
[2]黎喜梅.替吉奥为基础的化疗在消化道肿瘤中疗效与安全性的观察分析[J].中外医学研究,2017,15(20):138-140.
[3]刘昌娟.替吉奥为基础的化疗在消化道肿瘤中疗效与安全性的观察分析[J].中国继续医学教育,2017,9(28):96-98.
[4]王永杰.消化道肿瘤患者口服替吉奥化疗的临床效果观察[J].中国医药指南,2018,16(08):154-155.